HCW Biologics Inc.
13F holders, Q1 2024 (March 31)20holders
$1.73avg. 13F price*
At the end of Q1 2024, 20 institutions reported holding HCW Biologics Inc. in their 13F filings. The largest holders were HighTower Advisors, LLC ($316K), Avantax Planning Partners, Inc. ($315K) and Geode Capital Management, LLC ($291K).
- Company
- HCW Biologics Inc.
- CUSIP
- 40423R105
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $152K |
| Exits | 2 | $14K |
Ownership 20 holders
| HighTower Advisors, LLC | 0.00% | No change | 179,810 | $316K |
| Avantax Planning Partners, Inc. | 0.01% | Add +0.1% | 179,777 | $315K |
| Geode Capital Management, LLC | 0.00% | Add +29.6% | 174,284 | $291K |
| Cresset Asset Management, LLC | 0.00% | No change | 131,990 | $231K |
| Pullen Investment Management, LLC | 0.13% | — | 85,116 | $149K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 84,700 | $141K |
| HRT Financial LP | 0.00% | New | 73,113 | $122K |
| BlackRock Inc. | 0.00% | Reduce -2.4% | 46,034 | $81K |
| Vanguard Group Inc. | 0.00% | Reduce -81.7% | 37,649 | $66K |
| AE Wealth Management LLC | 0.00% | No change | 30,000 | $53K |
| Two Sigma Investments, LP | 0.00% | No change | 22,640 | $40K |
| State Street Corp. | 0.00% | No change | 21,446 | $36K |
| Jane Street Group, LLC | 0.00% | New | 17,247 | $30K |
| Northern Trust Corp. | 0.00% | No change | 10,205 | $18K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -12.9% | 4,938 | $9K |
| UBS Group AG | 0.00% | Reduce -4.7% | 605 | $1K |
| Bank of America Corp. | 0.00% | Add +3590.9% | 406 | $710 |
| Wells Fargo & Company | 0.00% | Add +2.2% | 141 | $247 |
| JPMorgan Chase & Co. | 0.00% | Reduce -89.2% | 9 | $15 |
| Royal Bank of Canada | 0.00% | Reduce -17.6% | 244 | $0 |
"% of holder's portfolio" is HCW BIOLOGICS INC's weight in each manager's 13F, not the share of HCW Biologics Inc. the manager owns.